Gitelman syndrome
Conditions
Interventions
Experimental group:Indomethacin 50mg-75mg once a day orally
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Serum potassium >= 2.5mmol/L and <3.5mmol/L; 2.Increased levels of prostaglandin metabolites in 24-hour urine; 3.In the 6 weeks before enrollment, stop spironolactone, NSAIDs, amiloride, ACEI/ARB and other drugs that might affect blood potassium levels, expect potassium and magnesium supplements; 4.Agree to participate in the study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1.Combined with moderate to severe renal insufficiency, eGFR < 60ml/min/1.73m2; 2.Combined with moderate to severe hepatic insufficiency, ALT or TBil more than 2 times higher than the upper limit of normal; 3.Combined with a history of active/recurrent gastrointestinal ulcer disease or bleeding; 4.Complicated with a history of aplastic anemia, leukopenia, thrombocytopenia; 5.Combined with bleeding disorders; 6.Combined with a history of myocardial infarction, heart failure, or stroke; 7.Combined with a history of epilepsy, Parkinson's disease, or mental illness; 8.Allergic to non-steroidal anti-inflammatory drugs; 9.Pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum potassium;Adverse reaction; | — |
Secondary
| Measure | Time frame |
|---|---|
| serum magnesium; | — |
Countries
China
Contacts
Public ContactChen Limeng
Peking Union Medical College Hospital
Outcome results
None listed